Cardiovascular toxicity of immune therapies for cancer
Immune-based therapies, like immune checkpoint inhibitors (ICIs) and chimeric antigen receptor T cell therapy (CAR-T), have seen increased use in cancer treatment. This has led to cardiovascular adverse events, including myocarditis, pericarditis, vasculitis, thromboembolism, and accelerated atherosclerosis. ICIs impact T cell activation, leading to myocardial inflammation in ICIMy, with combination therapy increasing the risk. CAR-T…